Effects of Vivatlac Synbiotic on the Gut Microbiota of Patients With Irritable Bowel Syndrome - A Randomized, Double-blind, Placebo-Controlled, 12 Weeks Clinical Trial
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Multi-center, randomized, double-blind, placebo-controlled, 12 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) on the gut microbiota of IBS patients
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• diagnosed for Irritable Bowel Syndrome using the IBS questionnaire for Health Care Providers of the World Global Gastroenterology Organization
• IBS severity assessed with the IBS-Severity Scoring System (IBS-SSS) being ≥ 175 points (indicating medium or severe IBS).
Locations
Other Locations
Poland
State Hospital Jarocin
RECRUITING
Jarocin
State Hospital Jarocin
RECRUITING
Jarocin
Contact Information
Primary
Jacek Piatek, Prof. Dr.
drpiatek@interia.eu
+48883389788
Backup
Henning Sommermeyer, Dr.
h.sommermeyer@uniwersytetkaliski.edu.pl
+420605434344
Time Frame
Start Date: 2025-11-21
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 20
Treatments
Placebo_comparator: Placebo
Capsule containing maize starch with identical appearance as verum. One capsule taken per day before bedtime. Treatment duration 12 weeks.
Experimental: Vivatlac Synbiotic
Vivatlac Synbiotic for 12 weeks. One capsule containing a mixture of nine different probiotic bacteria with a total amount of 4.5 x 10\^9 colony forming units and 63 mg of fructooligosaccharides. One capsule taken per day before bedtime. Treatment duration 12 weeks.
Related Therapeutic Areas
Sponsors
Leads: The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz